Erschienen in:
30.03.2019 | CE - Research Letter to the Editor
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease
verfasst von:
Felice Gragnano, Fabio Fimiani, Marco Di Maio, Arturo Cesaro, Giuseppe Limongelli, Davide Cattano, Paolo Calabrò
Erschienen in:
Internal and Emergency Medicine
|
Ausgabe 4/2019
Einloggen, um Zugang zu erhalten
Excerpt
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, acting by either accelerating atherosclerosis progression or inducing a prothrombotic/antifibrinolytic systemic milieu [
1‐
3]. Several studies support the relevant role of Lp(a) in the occurrence of coronary events, especially in patients with premature coronary artery disease (CAD) [
4‐
6]. However, the association of elevated Lp(a) levels with the risk of recurrent cardiovascular events in patients with a prior coronary event optimally treated with statins remains controversial [
7]. We sought to assess the impact of Lp(a) levels on the recurrence of cardiovascular events in patients with premature CAD treated with percutaneous coronary intervention (PCI). …